11 min listen
ACCEL Lite: ACC.23 Late-Breaker: Bempedoic Acid and Cardiovascular Outcomes In Statin Intolerant Patients At High Cardiovascular Risk
FromACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
ACCEL Lite: ACC.23 Late-Breaker: Bempedoic Acid and Cardiovascular Outcomes In Statin Intolerant Patients At High Cardiovascular Risk
FromACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
ratings:
Length:
11 minutes
Released:
Mar 28, 2023
Format:
Podcast episode
Description
Statin intolerance is one of the most vexing problems encountered by patients and providers. The CLEAR Outcomes trial directly addresses this problem, using a drug, bempedoic acid, that works only in the liver, thereby reducing the potential for side effects. In this interview, Steven E. Nissen MD, MACC and Laxmi Mehta MD, FACC, discuss Bempedoic Acid and Cardiovascular Outcomes In Statin Intolerant Patients At High Cardiovascular Risk. Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
Released:
Mar 28, 2023
Format:
Podcast episode
Titles in the series (100)
ACCEL Lite: Universal Definition of HF Syndrome: Evolving Strategies: The new universal heart failure (HF) definition will be easier for patients and clinicians to understand and will provide standardization across different societies. In this interview, Allen Taylor, MD, FACC; Biykem Bozkurt, MD, PhD, FACC; and... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research